Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme helps PTC develop and commercialize PTC124; terminated

Executive Summary

Genzyme will help PTC Therapeutics develop and commercialize its oral small-molecule Phase II PTC124 for genetic disorders caused by nonsense mutations. PTC keeps rights to the drug in the US and Canada, while Genzyme gets exclusive commercialization rights in all other countries.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register